A comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adult patients

References

• Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51:9–62.
   PubMed Web of Science ®Google Scholar
• Schoretsanitis G, Paulzen M, Unterecker S, et al. TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians. World J Biol Psychiatry. 2018;19:162–174.
   PubMed Web of Science ®Google Scholar
• Siskind D, Siskind V, Kisely S. Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis. Can J Psychiatry. 2017;62:772–777.
   PubMed Web of Science ®Google Scholar
• Zalsman G, Hawton K, Wasserman D, et al. Suicide prevention strategies revisited: 10-year systematic review. Lancet Psychiatry. 2016;3:646–659.
   PubMed Web of Science ®Google Scholar
• Zheng W, Xiang YT, Yang XH, et al. Clozapine augmentation with antiepileptic drugs for treatment-resistant schizophrenia: A meta-analysis of randomized controlled trials. J Clin Psychiatry. 2017;78:e498–e505.
   PubMed Web of Science ®Google Scholar
• Barber S, Olotu U, Corsi M, et al. Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. Cochrane Database Syst Rev. 2017;3:CD006324.
   PubMed Web of Science ®Google Scholar
• Wang G, Zheng W, Li XB, et al. ECT augmentation of clozapine for clozapine-resistant schizophrenia: A meta-analysis of randomized controlled trials. J Psychiatr Res. 2018;105:23–32.
   PubMed Web of Science ®Google Scholar
• Bai Z, Wang G, Cai S, et al. Efficacy, acceptability and tolerability of 8 atypical antipsychotics in Chinese patients with acute schizophrenia: A network meta-analysis. Schizophr Res. 2017;185:73–79.
   PubMed Web of Science ®Google Scholar
• Krause M, Zhu Y, Huhn M, et al. Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: A network meta-analysis. Eur Neuropsychopharmacol. 2018;28:659–674.
   PubMed Web of Science ®Google Scholar
• Frogley C, Taylor D, Dickens G, et al. A systematic review of the evidence of clozapine’s anti-aggressive effects. Int J Neuropsychopharmacol. 2012;15:1351–1371.
   PubMed Web of Science ®Google Scholar
• Krause M, Huhn M, Schneider-Thoma J, et al. Efficacy, acceptability and tolerability of antipsychotics in patients with schizophrenia and comorbid substance use. A systematic review and meta-analysis. Eur Neuropsychopharmacol. 2019;29:32–45.
   PubMed Web of Science ®Google Scholar
• Mentzel TQ, van der Snoek R, Lieverse R, et al. Clozapine monotherapy as a treatment for antipsychotic-induced tardive dyskinesia: A meta-analysis. J Clin Psychiatry. 2018;79(6):pii: 17r11852.
   PubMed Web of Science ®Google Scholar
• Li XB, Tang YL, Wang CY, et al. Clozapine for treatment-resistant bipolar disorder: A systematic review. Bipolar Disord. 2015;17:235–247.
   PubMed Web of Science ®Google Scholar
• Sabaawi M, Singh NN, de Leon J. Guidelines for the use of clozapine in individuals with developmental disabilities. Res Dev Disabil. 2006;27:309–336.
   PubMed Web of Science ®Google Scholar
• Rohde C, Hilker R, Siskind D, et al. Real-world effectiveness of clozapine for intellectual disability: results from a mirror-image and a reverse-mirror-image study. J Psychopharmacol. 2018;32:1197–1203.
   PubMed Web of Science ®Google Scholar
• Iketani R, Kawasaki Y, Yamada H. Comparative utility of atypical antipsychotics for the treatment of psychosis in Parkinson’s disease: a systematic review and Bayesian network meta-analysis. Biol Pharm Bull. 2017;40:1976–1982.
   PubMed Web of Science ®Google Scholar
• Kongsamut S, Roehr JE, Cai J, et al. Iloperidone binding to human and rat dopamine and 5-HT receptors. Eur J Pharmacol. 1993;317:417–423.
   Web of Science ®Google Scholar
• Burstein ES, Ma J, Wong S, et al. Intrinsic efficacy of antipsychotics at human D2, D3, and D4dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J Pharmacol Exp Ther. 2005;315:1278–1287.
   PubMed Web of Science ®Google Scholar
• Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000;68:29–39.
   PubMed Web of Science ®Google Scholar
• Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996;124:57–73.
   PubMed Web of Science ®Google Scholar
• Leysen JE, Janssen PM, Megens AA, et al. Risperidone: A novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994;55(Suppl):5–12.
   PubMed Web of Science ®Google Scholar
• Humbert-Claude M, Davenas E, Gbahou F, et al. Involvement of histamine receptors in the atypical antipsychotic profile of clozapine: a reassessment in vitro and in vivo. Psychopharmacology (Berl). 2012;220:225–241.
   PubMed Web of Science ®Google Scholar
• Sur C, Mallorga PJ, Wittmann M, et al. N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Pnas. 2003;100:13674–13679.
   PubMed Web of Science ®Google Scholar
• Seeman P. Clozapine, a fast-off-D2 antipsychotic. ACS Chem Neurosci. 2014;5:24–29.
   PubMed Web of Science ®Google Scholar
• Ramos Perdigués S, Sauras Quecuti R, Mané A, et al. An observational study of clozapine induced sedation and its pharmacological management. Eur Neuropsychopharmacol. 2016;26:156–161.
   PubMed Web of Science ®Google Scholar
• de Leon J, Odom-White A, Josiassen RC, et al. Serum antimuscarinic activity during clozapine treatment. J Clin Psychopharmacol. 2003;23:336–341.
   PubMed Web of Science ®Google Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis. Lancet. 2013;14(382):951–962.
   Web of Science ®Google Scholar
• Lameh J, Burstein E, Taylor E, et al. Pharmacology of N-desmethylclozapine. Pharmacol Ther. 2007;115:223–231.
   PubMed Web of Science ®Google Scholar
• Acadia Pharmaceuticals Inc. ACADIA pharmaceuticals announces results from ACP- 104 phase IIb schizophrenia trial. [ cited 2018 Nov 02]. Available from: https://www.businesswire.com/news/home/20080616005726/en/ACADIA-Pharmaceuticals-Announces-Results-ACP-104-Phase-IIb
   Google Scholar
• Horacek J, Bubenikova-Valesova V, Kopecek M, et al. Mechanisms of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006;20:389–409.
   PubMed Web of Science ®Google Scholar
• Thomas DR, Dada A, Jones GA, et al. N-desmethylclozapine (NDMC) is an antagonist at the human native muscarinic M1 receptor. Neuropharmacology. 2010;58:1206–1214.
   PubMed Web of Science ®Google Scholar
• Scarr E, Hopper S, Vos V, et al. Low levels of muscarinic M1 receptor-positive neurons in cortical layers III and V in Brodmann areas 9 and 17 from individuals with schizophrenia. J Psychiatry Neurosci. 2018;43:338–346.
   PubMed Web of Science ®Google Scholar
• Yohn SE, Conn PJ. Positive allosteric modulation of M1 and M4 muscarinic receptors as potential therapeutic treatments for schizophrenia. Neuropharmacology. 2018;136:438–448.
   PubMed Web of Science ®Google Scholar
• Lee ST, Ryu S, Nam HJ, et al. Determination of pharmacokinetic properties of clozapine and norclozapine in Korean schizophrenia patients. Int Clin Psychopharmacol. 2009;24:139–144.
   PubMed Web of Science ®Google Scholar
• Asenjo Lobos C, Komossa K, Rummel-Kluge C, et al. Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;11:CD006633.
   Google Scholar
• Cohen D, Bogers JP, van Dijk D, et al. Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy. J Clin Psychiatry. 2012;73:1307–1312.
   PubMed Web of Science ®Google Scholar
• Remington G, Lee J, Agid O, et al. Clozapine’s critical role in treatment resistant schizophrenia: ensuring both safety and use. Expert Opin Drug Saf. 2016;15:1193–1203.
   PubMed Web of Science ®Google Scholar
• American Pharmacist Association. Drug information handbook. 21st ed. Hudson, OH: Lexi-Comp, Inc; 2012.
   Google Scholar
• Miller DD. Review and management of clozapine side effects. J Clin Psychiatry. 2000;61:Suppl:14–7.
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals Corporation. Clozaril (clozapine) tablets. East Hanover, NJ. [ cited 2018 Nov 02]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019758s062lbl.pdf
   Google Scholar
• Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry. 1999;60(Suppl 10):5–14.
   PubMed Web of Science ®Google Scholar
• de Leon J, Santoro V, D’Arrigo C, et al. Interactions between antiepileptics and second-generation antipsychotics. Expert Opin Drug Metab Toxicol. 2012;8:311–334.
   PubMed Web of Science ®Google Scholar
• Appl H, Holzammer T, Dove S, et al. Interactions of recombinant human histamine H₁R, H₂R, H₃R, and H₄R receptors with 34 antidepressants and antipsychotics. Naunyn-Schmiedeberg’s Arch Pharmacol. 2012;385:145–170.
   Google Scholar
• Ekström J, Godoy T, Riva A. Clozapine: agonistic and antagonistic salivary actions. J Dent Res. 2010;89:276–280.
   PubMed Web of Science ®Google Scholar
• de Leon J. Paying attention to pharmacokinetic and pharmacodynamic mechanisms to progress in the area of anticholinergic use in geriatric patients. Curr Drug Metab. 2011;12:635–646.
   PubMed Web of Science ®Google Scholar
• Abrams P, Andersson KE, Buccafusco JJ, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol. 2006;148:565–578.
   PubMed Web of Science ®Google Scholar
• Davies MA, Compton-Toth BA, Hufeisen SJ, et al. The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine’s actions? Psychopharmacology (Berl). 2005;178:451–460.
   PubMed Web of Science ®Google Scholar
• Zorn SH, Jones SB, Ward KM, et al. Clozapine is a potent and selective muscarinic M4 receptor agonist. Eur J Pharmacol. 1994;269:R1–2.
   PubMed Web of Science ®Google Scholar
• Chen SY, Ravindran G, Zhang Q, et al. Treatment strategies for clozapine-induced sialorrhea: a systematic review and meta-analysis. CNS Drugs. 2019;33:225–238.
   PubMed Web of Science ®Google Scholar
• Meyer JM, Stahl SM. The clozapine handbook: Stahl’s handbooks. Cambridge, UK: Cambridge University Press; 2019.
   Google Scholar
• Man WH, Colen-de Koning JC, Schulte PF, et al. The effect of glycopyrrolate on nocturnal sialorrhea in patients using clozapine: a randomized, crossover, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2017;37:155–161.
   PubMed Web of Science ®Google Scholar
• Cicala G, Barbieri MA, Spina E, et al. A comprehensive review of swallowing difficulties and dysphagia associated with antipsychotics in adults. Expert Rev Clin Pharmacol. 2019;12:219–234.
   PubMed Web of Science ®Google Scholar
• Cohen D. Clozapine and gastrointestinal hypomotility. CNS Drugs. 2017;31:1083–1091.
   PubMed Web of Science ®Google Scholar
• de Leon J, Diaz FJ, Josiassen RC, et al. Weight gain during a double-blind multidosage clozapine study. J Clin Psychopharmacol. 2007;27:22–27.
   PubMed Web of Science ®Google Scholar
• Tek C, Kucukgoncu S, Guloksuz S, et al. Antipsychotic-induced weight gain in first-episode psychosis patients: A meta-analysis of differential effects of antipsychotic medications. Early Interv Psychiatry. 2016;10:193–202.
   PubMed Web of Science ®Google Scholar
• Kluge M, Schuld A, Himmerich H, et al. Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study. J Clin Psychopharmacol. 2007;27:662–666.
   PubMed Web of Science ®Google Scholar
• Lu ML, Lane HY, Lin SK, et al. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. J Clin Psychiatry. 2004;65:766–771.
   PubMed Web of Science ®Google Scholar
• Hartfield AW, Moore NA, Clifton PG. Effects of clozapine, olanzapine and haloperidol on the microstructure of ingestive behaviour in the rat. Psychopharmacol (Berl). 2003;167:115–122.
   PubMed Web of Science ®Google Scholar
• Alper K, Schwartz KA, Kolts RL, et al. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry. 2007;62:345–354.
   PubMed Web of Science ®Google Scholar
• Devinsky O, Honigfeld G, Patin J. Clozapine-related seizures. Neurology. 1991;41:369–371.
   PubMed Web of Science ®Google Scholar
• Torta R, Monaco F. Atypical antipsychotics and serotoninergic antidepressants in patients with epilepsy: pharmacodynamic considerations. Epilepsia. 2002;43(Suppl 2):8–13.
   PubMed Web of Science ®Google Scholar
• Bak TH, Bauer M, Schaub RT, et al. Myoclonus in patients treated with clozapine: A case series. J Clin Psychiatry. 1995;56:418–422.
   PubMed Web of Science ®Google Scholar
• Antelo RE, Stanilla JK, Martin-Llonch N. Myoclonic seizures and “leg folding” phenomena with clozapine therapy: report of two cases. Biol Psychiatry. 1994;36:759–762.
   PubMed Web of Science ®Google Scholar
• McCollum B, Barclay J, de Leon J. Unexpected falls during clozapine treatment explained by myoclonus. Prim Care Companion CNS Disord. 2018;20(1):pii: 17l02151.
   PubMedGoogle Scholar
• Ohno-Shosaku T, Sugawara Y, Muranishi C, et al. Effects of clozapine and N-desmethylclozapine on synaptic transmission at hippocampal inhibitory and excitatory synapses. Brain Res. 2011;1421:66–77.
   PubMed Web of Science ®Google Scholar
• Bertilsson L, Carrillo JA, Dahl ML, et al. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol. 1994;38:471–473.
   PubMed Web of Science ®Google Scholar
• Olesen OV, Linnet K. Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations. J Clin Pharmacol. 2001;41:823–832.
   PubMed Web of Science ®Google Scholar
• Dain JG, Nicoletti J, Ballard F. Biotransformation of clozapine in humans. Drug Metab Dispos. 1997;25:603–609.
   PubMed Web of Science ®Google Scholar
• Schaber G, Wiatr G, Wachsmuth H, et al. Isolation and identification of clozapine metabolites in patient urine. Drug Metab Dispos. 2001;29:923–931.
   PubMed Web of Science ®Google Scholar
• Schaber G, Stevens I, Gaertner HJ, et al. Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance. Br J Clin Pharmacol. 1998;46:453–459.
   PubMed Web of Science ®Google Scholar
• Loi CM, Smith DA, Dalvie D. Which metabolites circulate? Drug Metab Dispos. 2013;41(933–51).
   PubMed Web of Science ®Google Scholar
• de Leon J, Armstrong SC, Cozza KL. The dosing of atypical antipsychotics. Psychosomatics. 2005;46:262–273.
   PubMed Web of Science ®Google Scholar
• Jerling M, Lindström L, Bondesson U, et al. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit. 1994;16:368–374.
   PubMed Web of Science ®Google Scholar
• Spina E, de Leon J. Clinical applications of CYP genotyping in psychiatry. J Neural Transm (Vienna). 2015;122:5–28.
   PubMed Web of Science ®Google Scholar
• Ruan CJ, Zang YN, Wang CY, et al. Clozapine metabolism in east Asians and caucasians: A pilot exploration of the prevalence of poor metabolizers and a systematic review. J Clin Psychopharmacol. 2019;39:135–144.
   PubMed Web of Science ®Google Scholar
• Centorrino F, Baldessarini RJ, Flood JG, et al. Relation of leukocyte counts during clozapine treatment to serum concentrations of clozapine and metabolites. Am J Psychiatry. 1995;152:610–612.
   PubMed Web of Science ®Google Scholar
• Combs MD, Perry PJ, Bever KA. N-desmethylclozapine, an insensitive marker of clozapine-induced agranulocytosis and granulocytopenia. Pharmacotherapy. 1997;17:1300–1304.
   PubMed Web of Science ®Google Scholar
• Carrillo JA, Herraiz AG, Ramos SI, et al. Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients. J Clin Psychopharmacol. 1998;18:311–316.
   PubMed Web of Science ®Google Scholar
• Dumortier G, Lochu A, Zerrouk A, et al. Whole saliva and plasma levels of clozapine and desmethylclozapine. J Clin Pharm Ther. 1998;23:35–40.
   PubMed Web of Science ®Google Scholar
• Mauri MC, Rudelli R, Bravin S, et al. Clozapine metabolism rate as a possible index of drug-induced granulocytopenia. Psychopharmacology (Berl). 1998;137:341–344.
   PubMed Web of Science ®Google Scholar
• Ozdemir V, Kalow W, Posner P, et al. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite norclozapine steady-state concentration in patients with schizophrenia. J Clin Psychopharmacol. 2001;21:398–407.
   PubMed Web of Science ®Google Scholar
• Dailly E, Urien S, Chanut E, et al. Evidence from a population pharmacokinetics analysis for a major effect of CYP1A2 activity on inter- and intraindividual variations of clozapine clearance. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:699–703.
   PubMed Web of Science ®Google Scholar
• Palego L, Biondi L, Giannaccini G, et al. Clozapine, norclozapine plasma levels, their sum and ratio in 50 psychotic patients: influence of patient-related variables. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:473–480.
   PubMed Web of Science ®Google Scholar
• Rostami-Hodjegan A, Amin AM, Spencer EP, et al. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: A predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol. 2004;24:70–78.
   PubMed Web of Science ®Google Scholar
• Wang CY, Zhang ZJ, Li WB, et al. The differential effects of steady-state fluvoxamine on the pharmacokinetics of olanzapine and clozapine in healthy volunteers. J Clin Pharmacol. 2004;44:785–792.
   PubMed Web of Science ®Google Scholar
• Flanagan RJ, Spencer EP, Morgan PE, et al. Suspected clozapine poisoning in the UK/Eire, 1992-2003. Forensic Sci Int. 2005;155:91–99.
   PubMed Web of Science ®Google Scholar
• Raedler TJ, Hinkelmann K, Wiedemann K. Variability of the in vivo metabolism of clozapine. Clin Neuropharmacol. 2008;31:347–352.
   PubMed Web of Science ®Google Scholar
• Shad MU. Clozapine toxicity: A discussion of pharmacokinetic factors. Asian J Psychiatr. 2008;1:47–49.
   PubMedGoogle Scholar
• Benedetti A, Di Paolo A, Lastella M, et al. Augmentation of clozapine with aripiprazole in severe psychotic bipolar and schizoaffective disorders: a pilot study. Clin Pract Epidemiol Ment Health. 2010;6:30–35.
   PubMedGoogle Scholar
• Couchman L, Morgan PE, Spencer EP, et al. Plasma clozapine, norclozapine, and the clozapine: norclozapineratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993-2007. Ther Drug Monit. 2010;32:438–447.
   PubMed Web of Science ®Google Scholar
• Rajji TK, Uchida H, Ismail Z, et al. Clozapine and global cognition in schizophrenia. J Clin Psychopharmacol. 2010;30(4e):431–436.
   PubMed Web of Science ®Google Scholar
• Couchman L, Bowskill SV, Handley S, et al. Plasma clozapine and norclozapine in relation to prescribed dose and other factors in patients aged <18 years: data from a therapeutic drug monitoring service, 1994-2010. Early Interv Psychiatry. 2013;7:122–130.
   PubMed Web of Science ®Google Scholar
• Légaré N, Grégoire CA, De Benedictis L, et al. Increasing the clozapine: norclozapine ratio with co-administration of fluvoxamine to enhance efficacy and minimize side effects of clozapine therapy. Med Hypotheses. 2013;80:689–691.
   PubMed Web of Science ®Google Scholar
• Patteet L, Maudens KE, Vermeulen Z, et al. Retrospective evaluation of therapeutic drug monitoring of clozapine and norclozapine in Belgium using a multidrug UHPLC-MS/MS method. Clin Biochem. 2014;47:336–339.
   PubMed Web of Science ®Google Scholar
• Caetano D, Piatkov I. Higher than expected clozapine serum level and clozapine/norclozapine ratio due to CYP450 gene polymorphisms. Per Med. 2015;12:555–558.
   PubMed Web of Science ®Google Scholar
• Rajji TK, Mulsant BH, Davies S, et al. Prediction of working memory performance in schizophrenia by plasma ratio of clozapine to N-desmethylclozapine. Am J Psychiatry. 2015;172:579–585.
   PubMed Web of Science ®Google Scholar
• Molins C, Carceller-Sindreu M, Navarro H, et al. Plasma ratio of clozapine to N-desmethylclozapine can predict cognitive performance in treatment-resistant psychotic patients. Psychiatry Res. 2017;258:153–157.
   PubMed Web of Science ®Google Scholar
• Smith RL, Haslemo T, Andreassen OA, et al. Correlation between serum concentrations of N-desmethylclozapine and granulocyte levels in patients with schizophrenia: A retrospective observational study. CNS Drugs. 2017;31:991–997.
   PubMed Web of Science ®Google Scholar
• Marazziti D, Palego L, Betti L, et al. Effect of valproate and antidepressant drugs on clozapine metabolism in patients with psychotic mood disorders. Ther Drug Monit. 2018;40:443–451.
   PubMed Web of Science ®Google Scholar
• Reznik R, Chen RYY, Stanford P. Clozapine toxicity in a CYP2D6 poor metaboliser: additive effects of haloperidol and valproate on clozapine metabolism. Australas Psychiatry. 2018;26:608–611.
   PubMed Web of Science ®Google Scholar
• Volpicelli SA, Centorrino F, Puopolo PR, et al. Determination of clozapine, norclozapine and clozapine-N-oxide in serum by liquid chromatography. Clin Chem. 1993;39:1656–1659.
   PubMed Web of Science ®Google Scholar
• Troostwijk LJAE DV, Koopmans RP, Vermeulen HDB, et al. CYP1A2 activity is an important determinant of clozapine dosage in schizophrenic patients. Eur J Pharm Sci. 2003;20:451–457.
   PubMed Web of Science ®Google Scholar
• Mauri MC, Volonteri LS, Dell’ Osso B, et al. Predictors of clinical outcome in schizophrenic patients responding to clozapine. J Clin Psychopharmacol. 2003;23:660–664.
   PubMed Web of Science ®Google Scholar
• Weiner DM, Meltzer HY, Veinbergs I, et al. The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology (Berl). 2004;177:207–216.
   PubMed Web of Science ®Google Scholar
• Jecel J, Michel TM, Gutknecht L, et al. Toxic clozapine serum levels during acute urinary tract infection: a case report. Eur J Clin Pharmacol. 2005;60:909–910.
   PubMed Web of Science ®Google Scholar
• Bugamelli F, Mandrioli R, Kenndler E, et al. Possible levomepromazine-clozapine interactions. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:567–570.
   PubMed Web of Science ®Google Scholar
• Melkersson KI, Scordo MG, Gunes A, et al. Impact of CYP1A2 and CYP2D6 polymorphisms on drug metabolism and on insulin and lipid elevations and insulin resistance in clozapine-treated patients. J Clin Psychiatry. 2007;68:697–704.
   PubMed Web of Science ®Google Scholar
• Tang Y, Mao P, Li FM, et al. Gender, age, smoking behaviour and plasma clozapine concentrations in 193 Chinese inpatients with schizophrenia. Br J Clin Pharmacol. 2007;64:49–56.
   PubMed Web of Science ®Google Scholar
• Consoli G, Lastella M, Ciapparelli A, et al. ABCB1 polymorphisms are associated with clozapine plasma levels in psychotic patients. Pharmacogenetics. 2009;10:1267–1276.
   Google Scholar
• Murayama-Sung L, Ahmed I, Goebert D, et al. The impact of hospital smoking ban on clozapine and norclozapine levels. J Clin Psychopharmacol. 2011;31:124–126.
   PubMed Web of Science ®Google Scholar
• Farha KA, van Vliet A, Knetering H, et al. The value of desmethylclozapine and serum CRP in clozapine toxicity: A case report. Case Rep Psychiatry. 2012;2012:592784.
   PubMedGoogle Scholar
• Lee ST, Ryu S, Kim SR, et al. Association study of 27 annotated genes for clozapine pharmacogenetics validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response. J Clin Psychopharmacol. 2012;32:441–448.
   PubMed Web of Science ®Google Scholar
• Taieb A, B’chir F, Molinié R, et al. Relationships between clozapine and norclozapine plasma concentrations, clozapine dose, and clinical response in Tunisian patients with schizophrenia-treatment resistance. Open J Psychiatry. 2012;2:262–268.
   Google Scholar
• Leung JG, Nelson S, Takala CR, et al. Infection and inflammation leading to clozapine toxicity and intensive care: A case series. Ann Pharmacother. 2014;48:801–805.
   PubMed Web of Science ®Google Scholar
• Singh H, Dubin WR, Kaur S. Drug interactions affecting clozapine levels. J Psych Int Care. 2015;11:52–65.
   Google Scholar
• Thornton AE, Procyshyn RM, Barr AM, et al. Cognition and plasma ratio of clozapine to N-desmethylclozapine in patients with clozapine-resistant schizophrenia. Am J Psychiatry. 2015;172:1259.
   PubMed Web of Science ®Google Scholar
• Lee LH, White RF, Barr AM, et al. Elevated clozapine plasma concentration secondary to a urinary tract infection: proposed mechanisms. J Psychiatry Neurosci. 2016;41:E67–8.
   PubMed Web of Science ®Google Scholar
• Iglesias Garcia C, Iglesias Alonso A, Bobes J. Concentrations in plasma clozapine levels in schizophrenic and schizoaffective patients. Rev Psiq Sal Med. 2017;10:192–196.
   Google Scholar
• Jakobsen MI, Larsen JR, Svensson CK, et al. The significance of sampling time in therapeutic drug monitoring of clozapine. Acta Psychiatr Scand. 2017;135:159–169.
   PubMed Web of Science ®Google Scholar
• Piatkov I, Caetano D, Assur Y, et al. CYP2C19*17 protects against metabolic complications of clozapine treatment. World J Biol Psychiatry. 2017;18:521–527.
   PubMed Web of Science ®Google Scholar
• Toth K, Csukly G, Sirok D, et al. Potential role of patients’ CYP3A-status in clozapine pharmacokinetics. Int J Neuropsychopharmacol. 2017;20:529–537.
   PubMed Web of Science ®Google Scholar
• Clark SR, Warren NS, Kim G, et al. Elevated clozapine levels associated with infection: A systematic review. Schiz Res. 2018;192:50–56.
   PubMed Web of Science ®Google Scholar
• De Mel VN, Korman N, McArdie P, et al. Weight gain correlated with decrease in clozapine/N-desmethyl-clozapine ratio in a man with treatment-refractory schizophrenia. Australas Psychiatry. 2018;26:558–559.
   PubMed Web of Science ®Google Scholar
• Hommers L, Scharl M, Hefner G, et al. Comedication of valproic acid is associated with increased metabolism of clozapine. J Clin Psychopharmacol. 2018;38:188–192.
   PubMed Web of Science ®Google Scholar
• Lu ML, Chen TT, Kuo PH, et al. Effects of adjunctive fluvoxamine on metabolic parameters and psychopathology in clozapine-treated patients with schizophrenia: A 12-week, randomized, double-blind, placebo-controlled study. Schizophr Res. 2018;193:126–133.
   PubMed Web of Science ®Google Scholar
• McArdle PA, De Mel V, DeMonte V, et al. An investigation into the relationship between clozapine treatment and cognitive performance in patients with treatment resistant schizophrenia. Schizophr Res. 2018. DOI:10.1016/j.schres.2018.11.030.
   PubMed Web of Science ®Google Scholar
• Shymko G, Clark V, Shymko L, et al. Navigating the co-prescription of clozapine and fluvoxamine. Schizophr Res. 2018;202:391–393.
   PubMed Web of Science ®Google Scholar
• Augustin M, Schoretsanitis G, Pfeiffer P, et al. Effects of fluvoxamine augmentation and smoking on clozapine serum concentrations. Schizophr Res. 2019. In press.
   Google Scholar
• Hasegawa M, Gutierrez- Esteinou R, Way L, et al. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. J Clin Psychopharmacol. 1993;13:383–390.
   PubMed Web of Science ®Google Scholar
• Liu HC, Chang WH, Wei FC, et al. Monitoring of plasma clozapine levels and its metabolites in refractory schizophrenic patients. Ther Drug Monit. 1996;18:200–207.
   PubMed Web of Science ®Google Scholar
• Chang WH, Lin SK, Lane HY, et al. Clozapine dosages and plasma drug concentrations. J Formos Med Assoc. 1997;96:599–605.
   PubMed Web of Science ®Google Scholar
• Xiang YQ, Zhang ZJ, Weng YZ, et al. Serum concentrations of clozapine and norclozapine in the prediction of relapse of patients with schizophrenia. Schizophr Res. 2006;83:201–210.
   PubMed Web of Science ®Google Scholar
• Yusufi B, Mukherjee S, Flanagan R, et al. Prevalence and nature of side effects during clozapine maintenance treatment and the relationship with clozapine dose and plasma concentration. Int Clin Psychopathol. 2007;22:238–243.
   PubMed Web of Science ®Google Scholar
• Diaz FJ, Santoro V, Spina E, et al. Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. Pharmacopsychiatry. 2008;41:81–91.
   PubMed Web of Science ®Google Scholar
• Grande I, Pons A, Baeza I, et al. QTc prolongation: is clozapine safe? Study of 82 cases before and after clozapine treatment. Hum Psychopharmacol. 2011;26:397–403.
   PubMed Web of Science ®Google Scholar
• Ismail Z, Wessels AM, Uchida H, et al. Age and sex impact clozapine plasma concentrations in inpatients and outpatients with schizophrenia. Am J Geriatr Psychiatry. 2012;20:53–60.
   PubMed Web of Science ®Google Scholar
• Anderson SG, Livingston M, Couchman L, et al. Sex differences in plasma clozapine and norclozapine concentrations in clinical practice and in relation to body mass index and plasma glucose concentrations: A retrospective survey. Ann Gen Psychiatry. 2015;14:39.
   PubMed Web of Science ®Google Scholar
• Piwowarska J, Radziwon-Zaleska M, Dmochowska M, et al. The usefulness of monitored therapy using clozapine concentration in the blood serum for determining drug dose in Polish schizophrenic patients. Pharmacol Rep. 2016;68:1120–1125.
   PubMed Web of Science ®Google Scholar
• Lovdahl MJ, Perry PJ, Miller DD. The assay of clozapine and N-desmethylclozapine in human plasma by high-performance liquid chromatography. Ther Drug Monit. 1991;13:69–72.
   PubMed Web of Science ®Google Scholar
• Palego L, Del’ Osso L, Marazziti D, et al. Simultaneous analysis of clozapine, clomipramine and their metabolites by reversed-phase liquid chromatography. Prog Neuropsychopharmacol Biol Psychiatry. 2001;25:519–533.
   PubMed Web of Science ®Google Scholar
• Zhu R, Wang C, Zhao J, et al. Determination of clozapine and its N-demethylated metabolite in serum by gas chromatography-mass spectrometry with selected ion monitoring. Se Pu. 1998;16:317–320.
   PubMedGoogle Scholar
• McCarthy PT, Hughes S, Paton C. Measurement of clozapine and norclozapine in serum/plasma by high performance liquid chromatography with ultraviolet detection. Biomed Chromatogr. 1995;9:36–41.
   PubMed Web of Science ®Google Scholar
• Avenoso A, Facciola G, Campo GM, et al. Determination of clozapine, desmethylclozapine and clozapine N-oxide in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 1998;714:299–308.
   PubMed Web of Science ®Google Scholar
• Freeman DJ, Li MC, Oyewumi K. Solid-phase extraction and high-performance liquid chromatographic analysis of clozapine and norclozapine in human plasma. Ther Drug Monit. 1996;18:688–692.
   PubMed Web of Science ®Google Scholar
• Liu YY, Liu YY, van Troostwijk LJ, et al. Simultaneous determination of clozapine, norclozapine and clozapine-N-oxide in human plasma by high performance liquid chromatography with ultraviolet detection. Biomed Chromatogr. 2001;15:280–286.
   PubMed Web of Science ®Google Scholar
• Shapiro S. Is meta-analysis a valid approach to the evaluation of small effects in observational studies? J Clin Epidemiol. 1997;50:223–239.
   PubMed Web of Science ®Google Scholar
• Perry PJ, Miller DD, Arndt SV, et al. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry. 1991;148:231–235.
   PubMed Web of Science ®Google Scholar
• Jann MW, Liu HC, Wei FC, et al. Gender differences in plasma clozapine levels and its metabolites in schizophrenic patients. Hum Psychopharmacol. 1997;12:489–495.
   Web of Science ®Google Scholar
• Spina E, Avenoso A, Facciolà G, et al. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology (Berl). 2000;148:83–89.
   PubMed Web of Science ®Google Scholar
• Wong JO, Leung S, Mak T, et al. Plasma clozapine levels and clinical response in treatment-refractory Chinese schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:251–264.
   PubMed Web of Science ®Google Scholar
• Honer WG, Thornton AE, Chen EYH, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med. 2006;354:472–482.
   PubMed Web of Science ®Google Scholar
• Nordin C, Aim B, Bondesson U. CSF and serum concentrations of clozapine and its demethyl metabolite: A pilot study. Psychopharmacology (Berl). 1995;122:104–110.
   PubMed Web of Science ®Google Scholar
• Härtter S, Hüwel S, Lohmann T, et al. How does the benzamide antipsychotic amisulpride get into the brain? An in vitro approach comparing amisulpride with clozapine. Neuropsychopharmacology. 2003;28:1916–1922.
   PubMed Web of Science ®Google Scholar
• Schmitt U, Kirschbaum KM, Poller B, et al. In vitro P-glycoprotein efflux inhibition by atypical antipsychotics is in vivo nicely reflected by pharmacodynamic but less by pharmacokinetic changes. Pharmacol Biochem Behav. 2012;102:312–320.
   PubMed Web of Science ®Google Scholar
• El Ela AA, Härtter S, Schmitt U, et al. Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds–implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004;56:967–975.
   PubMed Web of Science ®Google Scholar
• Dickens D, Rädisch S, Chiduza GN, et al. Cellular uptake of the atypical antipsychotic clozapine is a carrier-mediated process. Mol Pharm. 2018;15:3557–3572.
   PubMed Web of Science ®Google Scholar
• Bowskill S, Couchman L, MacCabe JH, et al. Plasma clozapine and norclozapine in relation to prescribed dose and other factors in patients aged 65 years and over: data from a therapeutic drug monitoring service, 1996-2010. Hum Psychopharmacol. 2012;27:277–283.
   PubMed Web of Science ®Google Scholar
• Barclay J, McCollum B, Schoretsanitis G, et al. Gemfibrozil may decrease norclozapine elimination: A case report. J Clin Psychopharmacol. 2019;34.
   PubMed Web of Science ®Google Scholar
• Laupacis A, Straus S. Systematic reviews: time to address clinical and policy relevance as well as methodological rigor. Ann Intern Med. 2007;147:273–274.
   PubMed Web of Science ®Google Scholar
• de Leon J. Highlights of drug package inserts and the website DailyMed: the need for further improvement in package inserts to help busy prescribers. J Clin Psychopharmacol. 2011;31:263–265.
   PubMed Web of Science ®Google Scholar
• Schoretsanitis G, Spina E, Hiemke C, et al. A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone. Expert Rev Clin Pharmacol. 2017;10:965–981.
   PubMed Web of Science ®Google Scholar
• Schoretsanitis G, Spina E, Hiemke C, et al. A systematic review and combined analysis of therapeutic drug monitoring studies for oral paliperidone. Expert Rev Clin Pharmacol. 2018;11:625–639.
   PubMed Web of Science ®Google Scholar
• Schoretsanitis G, Spina E, Hiemke C, et al. A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone. Expert Rev Clin Pharmacol. 2018;11:1237–1253.
   PubMed Web of Science ®Google Scholar
• Lepist EI, Ray AS. Renal transporter-mediated drug-drug interactions: are they clinically relevant? J Clin Pharmacol. 2016;56(Suppl 7):S73–81.
   PubMed Web of Science ®Google Scholar
• Benet LZ, Broccatelli F, Oprea TI. BDDCS applied to over 900 drugs. Aaps J. 2011;13:519–547.
   PubMed Web of Science ®Google Scholar
• Tornio A, Neuvonen PJ, Niemi M, et al. Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters. Expert Opin Drug Metab Toxicol. 2017;13:83–95.
   PubMed Web of Science ®Google Scholar
• Horvitz-Lennon M, Mattke S, Predmore Z, et al. The role of antipsychotic plasma levels in the treatment of schizophrenia. Am J Psychiatry. 2017;174:421–426.
   PubMed Web of Science ®Google Scholar
• Lopez LV, Shaikh A, Merson J, et al. Accuracy of clinician assessments of medication status in the emergency setting: A comparison of clinician assessment of antipsychotic usage and plasma level determination. J Clin Psychopharmacol. 2017;37:310–314.
   PubMed Web of Science ®Google Scholar